Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET

Company Participants

Alex Lobo - IR

Milton Werner - CEO

Joseph Frattaroli - CFO

Conference Call Participants

Edward White - H.C. Wainwright

Operator

Hello, and welcome to the Inhibikase Therapeutics Third Quarter 2023 Financial Results. All participants will be in listen-only mode. [Operator Instructions] After the today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note today's event is being recorded.

I'll now turn the conference over to Alexander Lobo of Stern Investor Relations. Please go ahead, sir.

Alex Lobo

Thank you, operator. Good morning, and welcome to Inhibikase Therapeutics third quarter 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Tuesday, November 14, 2023 Inhibikase issued a press release announcing financial results for the third quarter ended September 30, 2023.

We encourage everyone to read yesterday's press release as well as Inhibikase's quarterly report on Form 10-Q, which has been filed with the SEC. The company's press release and quarterly report are also available on Inhibikase's website at inhibikase.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference.

Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 15, 2023.

Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live webcast, except as may be required by applicable securities law.

With that said, I would now like to turn the call over to Dr. Milton Werner. Milton you may begin.

Milton Werner

Thank you, Alex, and thank you, everyone, for joining us today. We are very pleased with the progress we've made throughout the third quarter as we have advanced our clinical and preclinical pipeline programs. In the clinic, we are continuing to evaluate the lead candidate, risvodetinib in our Phase II 201 trial in Parkinson's disease. The trial is actively screening and enrolling patients and activating the remaining clinical sites.